NOVO NORDISK CFO: AS VOLUMES OF WEGOVY, COMPETITOR ELI LILLY'S MOUNJARO CONTINUES TO EXPAND, PRICES WILL GO DOWN
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
923.2 DKK | -4.82% | -4.66% | +33.32% |
01:48pm | Novo Nordisk to Update Weight Loss Drugs Labels Over EMA's Safety Recommendation | MT |
10:56am | European shares slide as tech stocks weigh | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.32% | 63TCr | |
+56.97% | 85TCr | |
-0.27% | 36TCr | |
+15.53% | 32TCr | |
+12.70% | 30TCr | |
+15.04% | 24TCr | |
+16.98% | 23TCr | |
+16.49% | 18TCr | |
+4.58% | 17TCr | |
+2.68% | 13TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Cfo: As Volumes Of Wegovy, Competitor Eli Lilly's…